HRP20211590T1 - Farmaceutske kompozicije koje sadrže derivat fenilaminopirimidina - Google Patents
Farmaceutske kompozicije koje sadrže derivat fenilaminopirimidina Download PDFInfo
- Publication number
- HRP20211590T1 HRP20211590T1 HRP20211590TT HRP20211590T HRP20211590T1 HR P20211590 T1 HRP20211590 T1 HR P20211590T1 HR P20211590T T HRP20211590T T HR P20211590TT HR P20211590 T HRP20211590 T HR P20211590T HR P20211590 T1 HRP20211590 T1 HR P20211590T1
- Authority
- HR
- Croatia
- Prior art keywords
- nrc
- parts
- eudragit
- methacrylic acid
- formulation
- Prior art date
Links
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 18
- LCPGCGAJBOWMIP-UHFFFAOYSA-N n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-3,5-bis(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N=C(C=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LCPGCGAJBOWMIP-UHFFFAOYSA-N 0.000 claims 16
- 238000009472 formulation Methods 0.000 claims 14
- 229920003135 Eudragit® L 100-55 Polymers 0.000 claims 8
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims 8
- 229920003141 Eudragit® S 100 Polymers 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 229920000831 ionic polymer Polymers 0.000 claims 6
- 239000011159 matrix material Substances 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 5
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 4
- 229920002125 Sokalan® Polymers 0.000 claims 4
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000007962 solid dispersion Substances 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 3
- 229960003943 hypromellose Drugs 0.000 claims 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000012296 anti-solvent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- -1 defoamers Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000009474 hot melt extrusion Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000000935 solvent evaporation Methods 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Formulacija koja je pogodna za oralno davanje koja sadrži terapeutski efikasnu količinu (3,5-Bis trifluorometil)-N-[4-metil-3-(4-piridin-3il-pirimidin-2-il-amino)fenil]benzamida (NRC-AN-019) ili njegove soli, i bar jedno polimerno matrično sredstvo, gdje:
formulacija je u obliku čvrste disperzije; i
polimerno matrično sredstvo je ionski polimer ili ne-ionski polimer ili njihova kombinacija, pri čemu je ionski polimer celulozni polimer ili kopolimer metakrilne kiseline ili njihova kombinacija, i gdje je ne-ionski polimer celulozni polimer.
2. Formulacija prema zahtjevu 1, gdje NRC-AN-019 je u kristalnom ili amorfnom obliku ili njihovoj kombinaciji, poželjno gdje je NRC-AN-019 u kristalnom Obliku I, Obliku II, Obliku III ili njihovoj kombinaciji.
3. Formulacija prema bilo kojem od prethodnih zahtjeva, gdje je odnos NRC-AN-019 prema polimernom matričnom sredstvu od 1:1 do 1:8 u ukupnoj masi sastava.
4. Formulacija prema bilo kojem od prethodnih zahtjeva, gdje je ionski polimer kombinacija ionskog polimera i kopolimera metakrilne kiseline.
5. Formulacija prema bilo kojem od prethodnih zahtjeva, gdje je kopolimer metakrilne kiseline izabran od poli(metakrilne kiseline, metil metakrilata), poli(metakrilne kiseline, etil akrilata) i njihove kombinacije.
6. Formulacija prema bilo kojem od prethodnih zahtjeva, gdje je kopolimer metakrilne kiseline poli(metakrilna kiselina, metil metakrilat) i poli(metakrilna kiselina, etil akrilat).
7. Formulacija prema bilo kojem od prethodnih zahtjeva, gdje čvrsta disperzija dalje sadrži dodatnu farmaceutski prihvatljivu pomoćnu tvar izabranu od nosača, punjenja, površinski aktivnih sredstava, inhibitora kristalizacije, sredstava za zgušnjavanje, dezintegranata, plastifikatora, sredstava za uklanjanje pjene, antioksidansa, stabilizatora, glidanata i lubrikanata.
8. Formulacija prema zahtjevu 1, pri čemu se formulacija sastoji iz:
(a) 1 dijela NRC-AN-019, 2.5 dela Eudragit L 100 55, 4.5 dijela HPMCAS (hipromeloza acetat sukcinat) i 0.05 dijelova Carbopol 974;
(b) 1 dijela NRC-AN-019, 2 dijela Eudragit L 100 55, 1 dijela Eudragit S 100 i 0.05 dijelova Carbopol 974;
(c) 1 dijela NRC-AN-019, 2 dijela Eudragit L 100 55, 1 dijela Eudragit S 100 and 0.1 dijela Carbopol 974;
(d) 1 dijela NRC-AN-019, 4 dijela Eudragit L 100 55, 2 dijela Eudragit S 100 i 0.08 dijelova Carbopol 974;
(e) 1 dijela NRC-AN-019, 5 dijela Eudragit L 100 55 i 1 dijela HPMCP HP-55 (hipromeloza ftalat);
(f) 1 dijela NRC-AN-019, 5 dijela Eudragit L 100 55, 1 dijela Eudragit S 100, 1 dijela HPMCAS (hipromeloza acetat sukcinat) i 0.5 dijelova etil celuloze;
(g) 1 dijela NRC-AN-019, 5 dijela Eudragit L 100 55, 1 dijela Eudragit S 100 i 1 dijela HPMCP HP-55 (hipromeloza ftalata); ili
(h) 1 dijela NRC-AN-019, 5 dijela Eudragit L 100 55, 1 dijela Eudragit S 100, 1 dijela HPMCP HP-55 (hipromeloza ftalat) i 0.5 dijelova etil celuloze.
9. Formulacija prema bilo kojem od zahtjeva 1 do 7, pri čemu se čvrsta disperzija može dobiti taloženjem kontroliranim rastvaračem, isparavanjem rastvarača, liofilizacijom, pH kontroliranim taloženjem, ekstruzijom vrelim topljenjem i tehnologijom superkritičnog fluida.
10. Postupak za dobivanje čvrste disperzije prema zahtjevu 9, pri čemu postupak obuhvaća miješanje NRC-AN-019 i polimernog matričnog sredstva kao što je definirano u bilo kojem od zahtjeva 1 i 4 do 6 da bi se formirala homogena, molekularno disperzirana smjesa.
11. Postupak prema zahtjevu 10, pri čemu je miješanje izvedeno rastvaranjem NRC-AN-019 i polimernog matričnog sredstva u organskom rastvaraču, praćeno raspršivanjem u anti-rastvaraču i dobivanjem mješovitog taloga NRC-AN-019 i polimernog matričnog sredstva.
12. Postupak prema zahtjevu 11, gdje: rastvarač je dimetilformamid, dimetilacetamid, dimetilsulfoksid i N-Metil-2-pirolidon ili njihove smjese; ili gdje anti-rastvarač je voda, klorovodonična kiselina, etil acetat, toluen, metilen hlorid, acetonitril ili njihove smjese.
13. Formulacija kao što je definirano u bilo kojem od zahtjeva 1 do 9 za upotrebu u terapiji.
14. Formulacija kao što je definirano u bilo kojem od zahtjeva 1 do 9 za upotrebu u postupku liječenja karcinoma.
15. Formulacija prema zahtjevu 14 pri čemu je karcinom kronična mijeloidna leukemija, karcinom glave, karcinom vrata ili karcinom prostate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN6951CH2015 | 2015-12-18 | ||
| PCT/IN2016/050035 WO2017103941A1 (en) | 2015-12-18 | 2016-01-30 | Pharmaceutical compositions comprising phenylaminopyrimidine derivative |
| EP16875074.3A EP3389633B1 (en) | 2015-12-18 | 2016-01-30 | Pharmaceutical compositions comprising phenylaminopyrimidine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211590T1 true HRP20211590T1 (hr) | 2022-01-07 |
Family
ID=59055898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211590TT HRP20211590T1 (hr) | 2015-12-18 | 2016-01-30 | Farmaceutske kompozicije koje sadrže derivat fenilaminopirimidina |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US10383872B2 (hr) |
| EP (1) | EP3389633B1 (hr) |
| JP (2) | JP6896738B2 (hr) |
| KR (1) | KR20180102584A (hr) |
| CN (1) | CN108495620B (hr) |
| AU (1) | AU2016373574B2 (hr) |
| BR (1) | BR112018012458A2 (hr) |
| CA (1) | CA3008634A1 (hr) |
| CL (1) | CL2018001590A1 (hr) |
| CO (1) | CO2018007112A2 (hr) |
| CY (1) | CY1124580T1 (hr) |
| DK (1) | DK3389633T3 (hr) |
| EA (1) | EA036513B1 (hr) |
| ES (1) | ES2881883T3 (hr) |
| GB (1) | GB2564262A (hr) |
| GE (1) | GEP20207176B (hr) |
| HK (1) | HK1254573A1 (hr) |
| HR (1) | HRP20211590T1 (hr) |
| HU (1) | HUE056269T2 (hr) |
| IL (1) | IL260085B (hr) |
| LT (1) | LT3389633T (hr) |
| MA (1) | MA44079B1 (hr) |
| MX (1) | MX2018007281A (hr) |
| PH (1) | PH12018501292A1 (hr) |
| PL (1) | PL3389633T3 (hr) |
| PT (1) | PT3389633T (hr) |
| RS (1) | RS62422B1 (hr) |
| SG (1) | SG11201805142RA (hr) |
| SI (1) | SI3389633T1 (hr) |
| UA (1) | UA122592C2 (hr) |
| WO (1) | WO2017103941A1 (hr) |
| ZA (1) | ZA201804203B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物 |
| CZ2017821A3 (cs) * | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
| US20210369620A1 (en) * | 2018-05-14 | 2021-12-02 | Capsugel Belgium Nv | Solid dosage forms with high active agent loading |
| JP7368548B2 (ja) * | 2021-07-02 | 2023-10-24 | 昊運股▲フン▼有限公司 | 薬学的組成物及びその使用 |
| CN115583634B (zh) * | 2022-09-21 | 2023-06-06 | 广东工业大学 | 一种碳氮聚合物材料的制备方法及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241268A (ja) * | 2000-12-11 | 2002-08-28 | Takeda Chem Ind Ltd | 水溶解性が改善された医薬組成物 |
| CA2591321C (en) | 2004-09-09 | 2013-09-24 | Natco Pharma Limited | Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
| US8067422B2 (en) | 2008-03-04 | 2011-11-29 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
| WO2012002547A1 (ja) * | 2010-07-02 | 2012-01-05 | 富士化学工業株式会社 | ボセンタン固体分散体 |
| GB2488788B (en) | 2011-03-07 | 2013-07-10 | Natco Pharma Ltd | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
| CN102836159B (zh) * | 2011-06-24 | 2014-12-10 | 南京圣和药业股份有限公司 | 达沙替尼分散体及其制备方法和其在片剂中的应用 |
| JP2017500343A (ja) * | 2013-12-20 | 2017-01-05 | フォスフォレックス，インコーポレーテッド | インジルビン固体分散体組成物 |
-
2016
- 2016-01-30 CN CN201680079960.9A patent/CN108495620B/zh not_active Expired - Fee Related
- 2016-01-30 CA CA3008634A patent/CA3008634A1/en not_active Abandoned
- 2016-01-30 MX MX2018007281A patent/MX2018007281A/es active IP Right Grant
- 2016-01-30 KR KR1020187020546A patent/KR20180102584A/ko not_active Application Discontinuation
- 2016-01-30 RS RS20211232A patent/RS62422B1/sr unknown
- 2016-01-30 MA MA44079A patent/MA44079B1/fr unknown
- 2016-01-30 WO PCT/IN2016/050035 patent/WO2017103941A1/en active Application Filing
- 2016-01-30 US US16/062,320 patent/US10383872B2/en not_active Expired - Fee Related
- 2016-01-30 DK DK16875074.3T patent/DK3389633T3/da active
- 2016-01-30 GB GB1811142.7A patent/GB2564262A/en not_active Withdrawn
- 2016-01-30 HU HUE16875074A patent/HUE056269T2/hu unknown
- 2016-01-30 JP JP2018532262A patent/JP6896738B2/ja active Active
- 2016-01-30 AU AU2016373574A patent/AU2016373574B2/en not_active Expired - Fee Related
- 2016-01-30 PL PL16875074T patent/PL3389633T3/pl unknown
- 2016-01-30 EA EA201891443A patent/EA036513B1/ru unknown
- 2016-01-30 EP EP16875074.3A patent/EP3389633B1/en active Active
- 2016-01-30 ES ES16875074T patent/ES2881883T3/es active Active
- 2016-01-30 SI SI201631339T patent/SI3389633T1/sl unknown
- 2016-01-30 BR BR112018012458A patent/BR112018012458A2/pt not_active IP Right Cessation
- 2016-01-30 UA UAA201806892A patent/UA122592C2/uk unknown
- 2016-01-30 LT LTEPPCT/IN2016/050035T patent/LT3389633T/lt unknown
- 2016-01-30 PT PT168750743T patent/PT3389633T/pt unknown
- 2016-01-30 HR HRP20211590TT patent/HRP20211590T1/hr unknown
- 2016-01-30 GE GEAP201614833A patent/GEP20207176B/en unknown
- 2016-01-30 SG SG11201805142RA patent/SG11201805142RA/en unknown
-
2018
- 2018-06-14 CL CL2018001590A patent/CL2018001590A1/es unknown
- 2018-06-17 IL IL260085A patent/IL260085B/en unknown
- 2018-06-18 PH PH12018501292A patent/PH12018501292A1/en unknown
- 2018-06-22 ZA ZA2018/04203A patent/ZA201804203B/en unknown
- 2018-07-09 CO CONC2018/0007112A patent/CO2018007112A2/es unknown
- 2018-10-30 HK HK18113869.1A patent/HK1254573A1/zh unknown
-
2020
- 2020-12-03 JP JP2020201322A patent/JP2021059551A/ja not_active Withdrawn
-
2021
- 2021-10-13 CY CY20211100881T patent/CY1124580T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211590T1 (hr) | Farmaceutske kompozicije koje sadrže derivat fenilaminopirimidina | |
| JP6073043B2 (ja) | 医薬品適用のための熱−動力学的混合 | |
| US20140350027A1 (en) | Pharmaceutical Compositions Comprising Imatinib and a Release Retardant | |
| US20180369388A1 (en) | Pharmaceutical composition | |
| HRP20180068T1 (hr) | Formulacije lijeka s produljenim oslobađanjem | |
| HRP20211423T1 (hr) | Formulacije enzalutamida | |
| ES2922637T3 (es) | Forma de dosificación farmacéutica sólida de inhibidor de PARP y aplicación de forma de dosificación farmacéutica sólida de inhibidor de PARP | |
| JP6324930B2 (ja) | フェニルアラニン誘導体を含有する医薬製剤 | |
| ES2351947T3 (es) | Formulaciones orales de liberacion controlada de un inhibidor de la enzima convertidora de interleucina-1-beta. | |
| JP6537147B2 (ja) | 固体分散体 | |
| BR112017012706A2 (pt) | formulações de sunitinibe e métodos para uso destas no tratamento de transtornos oculares | |
| UY30686A1 (es) | "receptor nicotinico de acetilcolina, subtipo selectivo de amidas de diazabiciloalcanos" | |
| BRPI0714963A2 (pt) | processo de fabricaÇço de dispersÕes sàlidas de compostos terapÊuticos altamente cristalinos | |
| MX2017008939A (es) | Forma de dosificacion que incluye una solucion solida de drogas amorfas. | |
| RS52777B (en) | CURRENT RELEASE THERAPY SYSTEM FOR IMPROVED ORAL ABSORPTION 7 - [(E) -TERT-BUTYLOXYIMINOMETHYL] CAMPTOTECIN | |
| AU2015257658A1 (en) | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds | |
| PT1784169E (pt) | Matriz polimérica adesiva com grupos carboxílicos salificados para uso transdérmico | |
| ES2721849T3 (es) | Forma oral sólida dotada de un doble perfil de liberación que comprende multipartículas | |
| CN105078997A (zh) | 一种利伐沙班药用组合物及其制备方法 | |
| AR102571A1 (es) | Unidad de dispositivo con medicamento conteniendo quinagolida para uso en endometriosis, método | |
| HRP20220151T1 (hr) | Višenamjenski sastav torasemida | |
| JP2024516817A (ja) | ウリジントリアセテート非晶質製剤 | |
| ES2529443T3 (es) | Composición farmacéutica para tratar infecciones del HCV | |
| Pinto et al. | Cellulose ethers for extrusion applications | |
| KR101352867B1 (ko) | 동물용 복합항생제 조성물 |